Announced

Grünenthal to acquire Valinor Pharma for $250m.

Synopsis

Grünenthal, a science-based, fully integrated pharmaceutical company, agreed to acquire Valinor Pharma, a pharmaceutical company focused on innovative commercialization of medicines, for $250m. "As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio. The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal," Gabriel Baertschi, Grünenthal CEO.

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Grünenthal to acquire Valinor Pharma for $250m.